Novel Treatment Options of Binge Eating Disorder

D.      Marazziti; L.      Rossi; S.      Baroni; G.      Consoli; E.      Hollander; M.      Catena-Dell'Osso

doi:10.2174/092986711797636045

Abstract

Obesity is a major problem of modern societies that sometimes, but not necessarily, is associated with binge-eating disorder BED), a relatively new disorder characterized by binge eating without purging. The purpose of this article is to review the rationale for the potential use of pharmacological treatments in BED, and the potential use of the recently proposed compounds. Therefore, a careful medline of published articles from 1980 to December 2010 was carried out using the following keywords: BED and treatment, topiramate, zonisamide, sibutramine, venlafaxine, duloxetine, ghrelin, opiate blockers. Single case reports, observational studies, opinion articles, and studies concerning adults with syndromes resulting in BED (i.e., night eating syndrome) were also reviewed. All examined papers would indicate that the pharmacological treatment of BED is still heterogenous and poorly established, mainly for the lack of controlled studies in large samples of patients. In any case, the data on serotonin and norepinephrine reuptake inhibitors and on novel anticonvulsants seem quite promising in terms of efficacy and tolerability. In addition, the preliminary findings on the possibility of modulating appetite through the interference with the ghrelin system suggest new and intriguing ways of intervention in BED.

Keywords: Eating Disorders, Binge eating Disorder, Anticonvulsants, Topiramate, Zonisamide, SNRI, Opiate Blockers, Ghrelin, sibutramine, duloxetine